# An Integrated ODE Framework for Aging Hallmarks, Reliability Theory, and Gerotherapeutic Optimization

## Abstract
Aging emerges from coupled failures across molecular, cellular, and tissue-scale processes rather than from a single dominant lesion. Here, we present a literature-informed ordinary differential equation (ODE) framework that integrates seven interacting state variables representing telomere integrity, epigenetic integrity, mitochondrial function, senescent cell burden, inflammatory load, accumulated damage, and NAD+ availability. The model combines hallmark-of-aging biology with reliability theory and antagonistic pleiotropy concepts by representing aging as progressive damage accumulation tempered by finite repair capacity, while allowing survival-promoting pathways such as mTOR signaling to produce late-life liabilities. Interventions were modeled as continuous modifiers of mechanistic rates: senolytics increased senescent-cell clearance, caloric restriction activated AMPK/SIRT1-like protective terms, rapamycin suppressed mTORC1-dependent damage, and NAD+ precursors increased NAD+ synthesis and SIRT1-linked repair. Species differences were examined through metabolic scaling and allometric lifespan comparisons.

The calibrated baseline simulation reproduced qualitative features of human aging, including progressive declines in telomere, epigenetic, mitochondrial, and NAD+ states together with rising senescence, inflammation, and damage. Five-fold cross-validation over perturbed initial conditions yielded a control healthspan index of 32.956 ± 0.635 arbitrary units (AU). Predicted improvements were +9.6% for low-dose senolytics, +20.9% for high-dose senolytics, +5.0% for caloric restriction, +4.4% for rapamycin, +44.4% for NAD+ precursors, and +53.9% for a combined intervention. In the baseline trajectory, the senescent fraction exceeded 15% at 60.9 years, whereas senolytics delayed this transition to 91.2 years. Parameter perturbation analysis identified strong correlations among senescence, inflammation, mitochondrial decline, and epigenetic deterioration, supporting network-style aging dynamics.

This framework provides a transparent computational testbed for comparing geroscience interventions, exploring interaction structure among aging hallmarks, and identifying candidate multi-intervention regimes. Although not a patient-specific clinical model, it is useful for hypothesis generation, sensitivity analysis, and designing mechanistically interpretable in silico intervention studies.

## 1. Introduction
Aging is increasingly understood as a systems-level process in which multiple hallmarks interact nonlinearly across time. Telomere attrition, epigenetic drift, mitochondrial dysfunction, chronic inflammation, and senescent cell accumulation form a coupled network in which each lesion can amplify others. Reliability theory adds a useful conceptual layer by modeling organismal aging as a progressive loss of redundancy and increase in failure risk, while antagonistic pleiotropy explains why pathways beneficial for growth and reproduction early in life can accelerate late-life decline.

This study develops a unified ODE model for aging trajectories from age 20 to 100 years. The goals are to: (i) represent hallmark interactions mechanistically, (ii) integrate reliability-style damage accumulation, (iii) simulate interventions including senolytics, caloric restriction (CR), rapamycin, and NAD+ precursors, (iv) compare species-level lifespan trends via metabolic scaling, and (v) identify beneficial intervention combinations.

## 2. Related Work
The modern hallmark framework emphasizes interconnected biological drivers of aging and their shared causal architecture [1]. Mathematical models of senescence-linked disease have shown that coupled ODE systems can capture feedbacks between cellular senescence, inflammation, and tissue degeneration [2]. Epigenetic clock research further supports the use of state variables representing age-associated information loss [3]. Biomarker reviews highlight the need for quantitative frameworks that can compare intervention efficacy across multiple aging endpoints [4]. Chronic inflammation has been proposed both as a hallmark and as a cross-cutting amplifier of other hallmarks [5,6]. Additional work has shown that inflammation, metabolism, and epigenetic regulation converge on cellular senescence [7], while translational senolytic studies suggest that selective elimination of senescent cells is a promising gerotherapeutic strategy [8].

In contrast to single-process models, the present framework explicitly couples hallmark dynamics with intervention-responsive repair and damage terms, enabling comparison of monotherapies and combinations within a single numerical system.

## 3. Methods
### 3.1 State variables
The model contains seven continuous states:

- **T**: telomere integrity
- **E**: epigenetic integrity
- **M**: mitochondrial function
- **S**: senescent cell fraction
- **I**: inflammatory load
- **D**: accumulated damage / reliability index
- **N**: NAD+ level

All variables were normalized to the unit interval except senescent burden, which was capped at 0.5 for numerical stability.

### 3.2 ODE structure
The system implemented in `aging_model.py` uses the following forms:

- **Telomeres**:  
  dT/dt = -(rT_base + rT_ox(1-M)(1+I))T + prot_SIRT1_T·SIRT1·T
- **Epigenetic integrity**:  
  dE/dt = -(rE_base + rE_S·S + rE_I·I)E + prot_CR_E·AMPK·E + prot_SIRT1_E·SIRT1·E
- **Mitochondrial function**:  
  dM/dt = -(rM_base + rM_D·D + rM_I·I(1-M))M + regen_M_NAD·N(1-M) + regen_M_SIRT1·SIRT1(1-M) + mito_mTOR(1-mTOR)(1-M)·0.2
- **Senescent burden**:  
  dS/dt = kS_T(1-T)^2 + kS_E(1-E) + kS_M(1-M) + kS_bystander·I·S(0.5-S) - kS_clear·S(1-I) - senolytic_efficacy·S
- **Inflammation**:  
  dI/dt = kI_S·S + kI_base(1-M) - kI_clear·I(1+0.5·AMPK)
- **Damage / reliability**:  
  dD/dt = (kD_base(1+kD_I·I+kD_mTOR·mTOR) - kD_repair·repair_capacity·D)(1-D)
- **NAD+**:  
  dN/dt = NAD_synth(1+3·nad_supplement)(1+0.4·AMPK)(1-N) - (NAD_cons_base + NAD_cons_D·D + NAD_cons_I·I)N

where **AMPK = 0.8·CR + 0.3·rapamycin**, **mTOR = 1 - 0.85·rapamycin**, and **SIRT1 = N(1 + 2·nad_supplement)**.

### 3.3 Parameterization
Representative literature/NatureLM benchmarks used to guide the chosen rate scales were:

- Telomere shortening: ~50-100 bp per cell division; roughly 500-1000 bp/year as an upper-bound benchmark for proliferative human compartments, with lower leukocyte-average estimates also reported.
- Rapamycin: low-nanomolar mTORC1 inhibition (benchmark IC50 ≈ 1.6 nM; broader low-nM range reported) and ~20-30% lifespan extension in mice, with ~30% used as a target benchmark.
- NAD+ precursors (NMN/NR): commonly 2-10× increases in tissue NAD+, with >3× as a representative benchmark and associated SIRT1 activation.
- Caloric restriction: typically ~30-40% lifespan extension in mice, sometimes extending toward ~50% depending on strain and protocol, largely through AMPK/SIRT1, insulin/IGF-1, and FOXO-linked responses.
- Senolytics: modeled as 2-6% annual clearance in the main comparison and up to 10% annual clearance in the dose-response scan, reflecting literature statements that ~50-70% of senescent cells may be cleared per treatment cycle.

Default rate parameters are implemented exactly in the code and include `rT_base=0.008`, `rE_base=0.006`, `rM_base=0.005`, `kI_S=0.15`, `kD_base=0.01`, and `NAD_synth=0.06`.

### 3.4 Numerical methods
The ODE system was solved with `scipy.integrate.solve_ivp` (RK45, relative tolerance 1e-6, absolute tolerance 1e-8) over 80 years beginning from a young-adult baseline (age 20). A composite health score was defined as:

Health = clip((T + E + M + N)/4 - (S + I + D)/3, 0, 1)

and the healthspan index was computed as the trapezoidal area under this curve. Mortality was approximated using a Gompertz-like hazard:

μ = 0.001 · exp(8D + 3S + 2I - 2(T+E+M+N)/4)

### 3.5 Experimental design
Eight analyses were performed:
1. Baseline aging trajectories.
2. Intervention comparison across hallmarks.
3. Five-fold cross-validation of healthspan outcomes.
4. Gompertz mortality and survival curves.
5. Hallmark interaction heatmap under 100 parameter perturbation samples.
6. Species lifespan comparison using metabolic-rate and body-mass scaling.
7. Senolytic dose-response.
8. Rapamycin × caloric restriction grid search for healthspan optimization.

## 4. Experiments
### 4.1 Baseline simulation
The baseline run modeled untreated aging from age 20 to 100. The resulting trajectories provide a reference against which interventions were compared.

![Figure 1. Baseline human aging trajectories.](figures/fig1_baseline_aging.png)

### 4.2 Intervention comparison
Four intervention classes and a combined regime were simulated as continuous modifiers of relevant rates.

![Figure 2. Intervention effects on aging hallmarks.](figures/fig2_interventions.png)

### 4.3 Cross-validated healthspan comparison
Five folds were generated by perturbing initial conditions with small Gaussian noise.

![Figure 3. Cross-validated intervention healthspan comparison.](figures/fig3_healthspan_cv.png)

### 4.4 Mortality and survival
Hazard rates were converted into survival trajectories by numerical integration.

![Figure 4. Mortality and survival curves under different interventions.](figures/fig4_mortality_curves.png)

### 4.5 Interaction structure
A parameter perturbation ensemble was used to estimate pairwise correlations among late-life hallmark states.

![Figure 5. Hallmark interaction heatmap.](figures/fig5_hallmark_interactions.png)

### 4.6 Species-level scaling
Allometric and metabolic scaling relationships were visualized using literature lifespan values.

![Figure 6. Species lifespan comparison using metabolic and allometric scaling.](figures/fig6_species_lifespan.png)

### 4.7 Senolytic dose response
The model scanned senolytic clearance strength from 0 to 10% per year.

![Figure 7. Senolytic dose-response analysis.](figures/fig7_senolytic_dose_response.png)

### 4.8 Combination optimization
A 10 × 10 grid search was performed across rapamycin dose and caloric restriction intensity.

![Figure 8. Rapamycin × caloric restriction optimization grid.](figures/fig8_combination_optimization.png)

## 5. Results
### 5.1 Cross-validated healthspan outcomes
The main quantitative output from the simulation is summarized below.

| Intervention | Healthspan Index Mean ± SD (AU) | Improvement vs Control |
|---|---:|---:|
| Control | 32.956 ± 0.635 | +0.0% |
| Senolytics (low) | 36.112 ± 0.472 | +9.6% |
| Senolytics (high) | 39.839 ± 0.267 | +20.9% |
| Caloric Restriction | 34.598 ± 0.651 | +5.0% |
| Rapamycin | 34.418 ± 0.652 | +4.4% |
| NAD+ Precursors | 47.585 ± 0.867 | +44.4% |
| Combined (all) | 50.719 ± 0.396 | +53.9% |

### 5.2 Age-80 and age-100 summary statistics
Additional outputs derived from the executed model run are shown below.

| Intervention | Senescence at 80 | Inflammation at 80 | Damage at 80 | NAD+ at 80 | Composite Health at 80 | Survival to 100 (%) |
|---|---:|---:|---:|---:|---:|---:|
| Control | 0.297 | 0.303 | 0.397 | 0.521 | 0.177 | 4.479 |
| Senolytics (low) | 0.204 | 0.219 | 0.396 | 0.527 | 0.253 | 22.738 |
| Senolytics (high) | 0.119 | 0.138 | 0.395 | 0.533 | 0.328 | 44.493 |
| Caloric Restriction | 0.282 | 0.265 | 0.392 | 0.547 | 0.216 | 9.396 |
| Rapamycin | 0.283 | 0.272 | 0.390 | 0.541 | 0.213 | 9.252 |
| NAD+ Precursors | 0.201 | 0.212 | 0.221 | 0.770 | 0.466 | 78.481 |
| Combined (all) | 0.105 | 0.107 | 0.258 | 0.751 | 0.528 | 83.535 |

### 5.3 Combination optimization and senescence timing
The rapamycin × CR grid search identified the highest healthspan score at maximal tested values:

- Optimal rapamycin dose: **1.00** (relative units)
- Optimal caloric restriction intensity: **0.50**
- Optimal healthspan index: **38.815 AU**

The baseline trajectory crossed a senescent fraction of 15% at **60.9 years**, while high-efficacy senolytics delayed this transition to **91.2 years**.

### 5.4 Hallmark interaction structure
Strong parameter-ensemble correlations (|r| > 0.5) included:

- Telomere ↔ Senescence: **r = -0.590**
- Epigenetic ↔ Senescence: **r = -0.781**
- Epigenetic ↔ Inflammation: **r = -0.654**
- Mitochondrial ↔ Senescence: **r = -0.643**
- Mitochondrial ↔ Inflammation: **r = -0.555**
- Mitochondrial ↔ Damage: **r = -0.607**
- Senescence ↔ Inflammation: **r = 0.793**

These results support the interpretation that senescence and inflammation act as central amplifiers in the network.

## 6. Discussion
The simulations suggest three main conclusions. First, hallmark interactions generate nonlinear aging trajectories in which modest deterioration in one domain propagates into others. Second, interventions targeting repair capacity and network feedbacks can outperform interventions that act mainly on a single upstream node. In this parameterization, NAD+ boosting was especially effective because it improves mitochondrial restoration, raises SIRT1-linked protection, and increases damage repair simultaneously. Third, combined intervention strategies outperformed monotherapies, consistent with the idea that aging is multi-causal.

The model also illustrates antagonistic pleiotropy: pathways associated with nutrient sensing and growth can support early-life robustness but later contribute to damage and reduced autophagic quality control. Reliability-theory behavior appears through the cumulative damage variable, which accelerates mortality as repair capacity declines.

Important limitations remain. Parameter values are literature-informed rather than fitted to longitudinal human cohorts. Continuous intervention terms simplify pulsatile dosing. The species comparison is illustrative, not mechanistically coupled to the human ODE system. Finally, the strong apparent benefit of NAD+ precursors reflects the chosen coupling structure and should be interpreted as a hypothesis rather than a clinical claim.

## 7. Conclusion
We implemented and executed a complete ODE-based simulation framework linking hallmark interactions, senescence, inflammation, reliability-style damage, metabolic scaling, and intervention optimization. The model reproduced plausible qualitative aging patterns and generated interpretable quantitative predictions, including large gains for multi-target combinations. The code and figures provide a reusable basis for future parameter fitting, sensitivity analysis, and integration with experimental biomarker datasets.

## References
1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. **Hallmarks of aging: An expanding universe.** *Cell.* 2023;186(2):243-278. DOI: 10.1016/j.cell.2022.11.001
2. Siewe N, Friedman A. **Osteoporosis induced by cellular senescence: A mathematical model.** *PLoS ONE.* 2024;19(5):e0303978. DOI: 10.1371/journal.pone.0303978
3. Bell CG, Lowe R, Adams PD, et al. **DNA methylation aging clocks: challenges and recommendations.** *Genome Biology.* 2019;20:249. DOI: 10.1186/s13059-019-1824-y
4. Moqri M, Herzog C, Poganik JR, et al. **Biomarkers of aging for the identification and evaluation of longevity interventions.** *Cell.* 2023;186(18):3758-3775. DOI: 10.1016/j.cell.2023.08.003
5. Baechle JJ, Meza-Sosa KF, Lamfers MLM, et al. **Chronic inflammation and the hallmarks of aging.** *Molecular Metabolism.* 2023;77:101755. DOI: 10.1016/j.molmet.2023.101755
6. Li X, Li C, Zhang W, et al. **Inflammation and aging: signaling pathways and intervention therapies.** *Signal Transduction and Targeted Therapy.* 2023;8:239. DOI: 10.1038/s41392-023-01502-8
7. Zhu Y, Liu X, Ding X, Wang F, Geng X. **Inflammation, epigenetics, and metabolism converge to cell senescence and ageing.** *Signal Transduction and Targeted Therapy.* 2021;6:245. DOI: 10.1038/s41392-021-00646-9
8. Rießland J, Orr ME. **Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics.** *Journal of Prevention of Alzheimer's Disease.* 2023;10(4):579-590. DOI: 10.14283/jpad.2023.104
